12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

SNS01-T regulatory update

FDA granted Orphan Drug designation for Senesco's SNS01-T to treat mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL). Senesco plans to start Phase II testing of...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >